331 results about "Immune deficiency syndrome" patented technology

This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.

New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.

The invention discloses a CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9 recombinant lentiviral vector containing gRNA sequence specifically targeting CCR5 and application thereof. A lentivirus of the CRISPR/Cas9 recombinant lentiviral vector containing gRNA sequence specifically targeting CCR5 gene Delta 32 region is constructed that the lentivirus can introduce cells into a CRISPR/Cas9 system specific to CCR5, double-chain breakage occurs to a specific site of CCR5 gene, a random mutation is introduced to a breakage site after repairing by means of nonhomogeneous recombinant terminal binding, and the mutation rate reaches 90% and above. As gRNA is a nonhomogeneous region of CCR5 and CCR2, detection shows that the missing efficiency of the two gRNAs is lower than 0.2%. Cells modified via the recombinant lentivirus have significantly decreased efficiency of HIV (human immunodeficiency virus) infection. The system is quick to construct, simple and low in price, and is applicable to gene therapy of acquired immune deficiency syndrome.

The invention discloses sgRNA for specific targeting of a human CXCR4 gene, a sgRNA-containing staphylococcus aureus CRISPR/SaCas9 system and a method for specific human CXCR4 gene knockout by the method. A target sequence of sgRNA is shown as any one of SEQ ID NO:1-4. sgRNA for specific targeting of the human CXCR4 gene and AAV-CRISPR/SaCas9 plasmids are connected to form a carrier and packaged into AAV infection cells, simplicity, convenience, high efficiency and specificity in CXCR4 gene knockout are realized, and accordingly the problem of limitation in adoption of SpCas9 targeted CXCR4 for treatment of acquired immune deficiency syndrome is effectively solved.

The invention provides a completely oral medicament for treating acquired immune deficiency syndrome (AIDS), comprising the following components: hedyotis diffusa, honeysuckle, meadowrueleaf corydalis root, dandelion, weeping forsythia, asparagus, ophiopogon root, figwort root, fresh rehmannia root, peach kernel, chuanxiong rhizome, zedoary, achyranthes root, dahurian patrinia herb, giant knotweed, stiff silkworm, isatis root, white peony root, polygonatum, bitter caramon, mistletoe, tortoise plastron, glossy privet fruit, oyster, pollen, salvia miltiorrhiza, tree peony bark, bupleurum, bitter orange, cimicifuga foetida, dried orange peel, amomum fruit, officinal magnolia bark, rose, songaria cynomorium herb, self-heal, medicine terminalia fruit, gromwell, licorice, chrysanthemum, castor bean, bullfrog gallbladder, baikal skullcap root, medicated leaven, malt, rice sprout, chicken's gizzard-skin, radish seed, scorch-fried crataegus, Chinese yam, astragalus root, bighead atractylodes rhizome, sealwort, dangshen, prepared rehmannia root, cornus fruit, tuckahoe, jujube, Chinese wolfberry, cistanche, dragon bone, oyster, epimedium, curculigo root, deerhorn glue, ginseng, donkey-hide glue, white fungus, angelica, spatholobus stem and turtle shell. The medicament provided by the invention not only can cure AIDS and has good therapeutic effect on AIDS, but also can prevent infection of AIDS.

The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

The invention relates to a polyamine micromolecular compound, comprising the following structures described in the specification, wherein M<x+> is 0, Zn<2+>, Ga<3+>, Gd<3+>, Ca<2+> or other divalent metal ions and trivalent metal ions; S is a reporter group (including a nuclide labeling prothetic group, a paramagnet, a fluorescein or a microvesicle), such as the nuclide labeling prothetic group: -<11>CH3, -CH2CH2<18>F, -CH2CH2(OCH2CH2)2NHCOC6H4<18>F-p or -CH2CH2(OCH2CH2)2NH-CH2CH2<18>F; R is -H, -OCH3, -OCH2CH3 or -Cl; and R1, R2, R3 and R4 are hydrogen, carboxyl, alkane, alkylene or heteroalkyl. The invention further relates to application of the compound in preparing cell death or apoptosis developers of target phosphatidyl serine (PS) and/or apoptotic cell early free Zn<2+>. The compound provided by the invention is a specific multiamine micromolecular developer for target phosphatidyl serine (PS) and/or apoptotic cell early free Zn<2+>, which can be used for monitoring curative effects of PS-related anti-tumor chemotherapy, radiotherapy, biological therapy and the like; the compound can be used for early differential diagnosis of neurodegenerative diseases (senile dementia and Parkinson's disease), cerebral apoplexy, AIDS (Acquired immune deficiency syndrome), thrombus, atheromatous plaque and myocardial infarction; and the compound can also be used for differential diagnosis and curative effect monitoring of other diseases related to PS expression in the cell death or apoptosis process, such as inflammation development and anti-inflammation therapeutic development.

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.

The invention discloses a preparation method of an AIDS (acquired immune deficiency syndrome) virus affinity adsorbent. According to the method, amino acid is utilized to process virus adsorption microspheres connected with ligands, the ligands on the virus adsorption microspheres are combined more firmly, so that the probability and the speed of falling of the AIDS virus affinity adsorbent are reduced, and the safety of the AIDS virus affinity adsorbent during applying is improved.

The invention relates to a phosphonate prodrug of an adenine derivative and medical application of the phosphonate prodrug. Specifically, the invention relates to a compound shown in a general formula (I) or an optical isomer, or a pharmaceutical salt, or a hydrate or a solvate of the compound, and application of the compound or the optical isomer, or the pharmaceutical salt, or the hydrate or the solvate of the compound to preparation of medicines for curing virus infective diseases, especially hepatitis B (HBV) and acquired immune deficiency syndrome (HIV), wherein the definitions of all substituents in the general formula (I) are the same as the definitions in the specification.

The invention relates to a triazole ring-containing phenylalanine derivative as well as a preparation method and application thereof. A compound has a structure shown in formula I. The invention alsorelates to a medicine composition containing the compound with the structure shown in the formula I, and also provides application of the compound and the composition containing one or multiple compounds in preparation of medicines for treating and preventing acquired immune deficiency syndrome. (The formula I is shown in the attached figure.).

The present invention relates to novel 3-nitropyridine derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same as active ingredients. Methods of preparing the derivatives and pharmaceutical compositions containing the same are also disclosed. The 3-nitropyridine derivatives of the present invention, due to their inhibitory activity against the proliferation of human immunodeficiency virus (HIV) as well as hepatitis B virus (HBV), can be used as therapeutic agents as well as preventive agents for hepatitis B and acquired immune deficiency syndrome (AIDS).

The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O)₂—, —C(═S)— and P(═O)(R⁵)—; B is, —O—, —(CH₂)_3-6—, and O—(CH₂)_2-5—; D is, —O—, —CR⁷R⁸— and —NR⁹; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R¹ is opt.sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimers disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.

The present invention relates to select peptides of the carboxy terminal and aminoterminal portion of the beta unit of hCG and pharmaceutically acceptable derivatives thereof that can be used for controlling retroviral, e.g., human immunodeficiency virus (BV infections. The invention comprises a method in vitro as well as in vivo for prevention and/or treatment of acquired immune deficiency syndrome (AIDS) at pharmacological doses of beta hCG-derived peptides and pharmaceutically acceptable derivatives thereof which are sufficient to exert an anti-HIV effect for a sufficient period of time.

The invention discloses an AIDS (acquired immune deficiency syndrome) personnel behavior analysis method based on deep learning. The method comprises the following steps: acquiring user behavior data;and based on the user behavior data, analyzing the multi-dimensional space-time information of the user, and constructing a user behavior portrait. Behavior portraying is performed on the AIDS patient based on network, geographic position and social communication behavior analysis, and descriptive label attributes for the user are constructed in multiple dimensions such as network, geographic position and social communication. The label attributes are utilized to describe and outline the real personal characteristics of the AIDS patient in multiple aspects, and are used for describing relatedcharacteristics, behaviors and preferences. Potential social communication rules of AIDS crowds are discovered, high-risk AIDS crowds, potential AIDS propagators and AIDS propagation paths are discovered, and the AIDS intervention link work is assisted to be intervened in advance.

The invention discloses an Aapplication of a benzamide compound in preparation of a medicine for activating latent human immunodeficiency viruses, and an application of a composition of the benzamide compound and one or more anti-human immunodeficiency virus medicines in preparation of a medicine for inhibiting and/or eliminating latent human immunodeficiency viruses. Due to adoption of the medicine, the latent human immunodeficiency viruses can be efficiently and continuously activating latent human immunodeficiency viruses for a long time, and thus acquired immune deficiency syndrome treatment is possible.

The present invention belongs to the field of pharmaceutical industry and relates to dosage forms comprising active pharmaceutical ingredients (API) such as tadalafil, simvastatin, fenofibrate and lovastatin that are practically insoluble in water, adsorbed on a carrier. Furthermore it relates to an adsorbate comprising API being practically insoluble in water and to a process for the preparation of said adsorbate with non-polar solvent (s) such as chlorinated hydrocarbon, diisopropylethes and hexane. Furthermore the invention relates to a process for the preparation of the dosage form, as well as to the use of the adsorbate for the preparation of the dosage form. Moreover it relates to the dosage form for use in the treatment of erectile dysfunction, human immunodeficiency virus (HIV) infections and/or Acquired Immune Deficiency Syndrome (AIDS).

A natural pharmaceutical preparation for treating hypoproteinemia, includes at least one member selected from the group consisting of a drug of increasing human serum albium, a drug of improving and enhance immunity, a drug of treating hepatitis B, a drug of treating Hepatitis C, a drug of treating acquired immune deficiency syndrome (AIDS), a drug of treating Tuberculosis, a drug of treat Fibrosis, a drug of treating hydrothorax, a drug of easing pain, a drug of stopping diarrhea, a drug of arresting coughing, a drug of reducing inflammation, and a drug of increasing urine.

The invention discloses application of parthenolide as a platelet-activating factor (PAF) inhibitor. The parthenolide can be used as a safe PAF antagonist to be applied to treatment, auxiliary treatment and prevention of diseases such as thrombus, atherosclerosis, ischemic cardio-vascular disease, cerebral ischemia, acute pancreatitis, endotoxic shock, asthma, hepatic fibrosis and hepatocirrhosis, injury of nerve, gastrointestinal ulcer and necrosis, psoriasis, systemic lupus erythematosus and acquired immune deficiency syndrome related to platelet-activating factor.

The invention relates to a simple, convenient and high-efficiency synthesis method of 4-chloro-2-trifluoroacetylaniline and analogs thereof. The 4-chloro-2-trifluoroacetylaniline can be used as a key midbody for synthesizing the anti-AIDS (Acquired Immune Deficiency Syndrome) drug efavirenz.